summari report result close april
revenu in-lin consensu estim miss
estim due neg impact fx driven
slightli better expect net oper margin om
lower effect tax rate ep came
better consensu expect overal stryker
deliv anoth strong quarter organ growth y/i
fall upper-end compani prior full year
outlook underli busi momentum remain
strong rais lower-end full year revenu
outlook lower-end ep
outlook result lower
revenu estim reflect higher fx
headwind maintain ep estim
rais low-end outlook today
call modestli revis outlook top line
compani expect organ sale growth rang
versu compani prior outlook
highest initi revenu growth guidanc decad
fx expect approxim prior
headwind full year includ
one extra day fall compani
previous note growth vari quarter due
follow factor typic season due
tend stronger time product launch ramp
anniversari acquisit ktwo
manag maintain outlook deliv oper
margin om improv full year reiter
acquisit integr cost like pressur om
evid margin y/i
compani also maintain effect tax rate outlook
full year despit lower rate due exercis
stock option previous guid capital-expenditure
bottom line manag expect
ep rang versu prior outlook
compar estim prior
consensu manag quantifi neg impact
fx ep expect expect prior
full year includ net-
net expect ep rang
mid-point slightli prior consensu estim
prior estim overal revenu
estim reflect organ revenu growth om
expans full year deliv ep growth y/i
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report ep cash basi exclud amort
compani data secur llc estim reuter
continu previou page
mako momentum expect continu place system quarter includ
us rel system includ us prior year quarter
manag expect momentum mako adopt continu pipelin prospect
remain strong favor clinic data support mako compani global instal
base stand includ us quarter approxim
system place competit account surgeon train also continu nice
clip consist averag pace quarterli addit bring total
train approxim mako util approxim procedur us
versu includ mako tka procedur versu util
rate y/i consist sequenti quarter
orthoped adjust organ sale growth y/i came in-lin estim
orthoped sale estim due fx organ growth
spot overal hip knee organ growth better trauma extrem growth
project us organ growth y/i estim due delay
time product launch trauma continu declin bone cement driven strong uptak
syk cementless offer time bulk order somewhat off-set robust y/i
growth knee mid-teen growth orthoped capit off-set manag note call
knee segment growth led strong demand mako tka platform expect continu
drive share gain go forward well uptak cementless knee print product
us trauma grew versu estim due tough y/i comparison well delay full
commerci launch compani alpha syk next gener nail system roll
push mid-year drive uptak outsid us orthoped sale
y/i driven growth europ australia emerg market especi china
global recon market growth look sequenti big four recon hip
knee implant compani report result make nearli
global recon market result suggest global recon market sequenti
versu led acceler global hip versu fairli
flat sequenti growth global knee us recon market
sequenti versu growth led us knee expect get
clariti recon market growth rate snn report earn
medsurg adjust organ sale growth exceed estim
report medsurg sale exceed estim despit greater fx headwind
deliv ex-fx growth y/i versu estim organ growth
ahead estim segment growth broad-bas strong growth across
busi us medsurg growth led solid growth instrument deliv
y/i growth versu y/i estim driven uptak power tool wast manag
product us endoscopi growth y/i also exceed estim driven strong
uptak across novadaq sport medicin procar busi notabl
launch new video platform late expect drive meaning growth
final us medic growth came estim overal growth
led good perform bed stretcher busi outsid us medsurg growth
y/i led china emerg market off-set softer perform japan
australia due time order
neurotechnolog spine organ sale growth miss estim
report segment sale came estim underli organ
growth came estim overal segment growth led
neurotech product includ high-teen growth neurovascular off-set integration-rel disrupt
us spine us neurotech deliv organ growth led strong double-digit growth
neurovascular busi off-set expect soft neuro power instrument ahead
compani plan launch sonopet iq manag note call continu see strong
demand hemorrhag ischem stroke product spine note make
progress integr acquisit focu drive cost synergi sale
integr also on-going sale forc disrupt us within compani expect
notabl deliv pro forma growth maintain outlook deliv mid-
singl digit growth full year global spine franchis outsid us neurotech
spine deliv robust organ growth nearli doubl versu project
robust growth driven strong demand europ china emerg market
continu next page
oper margin expans back-end load maintain outlook
oper margin expans full year due time integr relat disrupt
compani note acquisition-rel dilut would impli strong underli margin
expans gross margin y/i due posit benefit acquisit
ktwo off-set price busi mix higher medsurg growth sg
y/i driven compani transform growth ctg program includ
key project focus indirect purchas share servic off-set neg impact
acquisit continu plan invest ctg program erp enterpris resourc
plan initi expand includ recent acquisit sale
y/i net-net deliv adjust oper margin y/i
reflect oper leverag cost save off-set invest acquisition-rel dilut
adjust effect tax rate came reflect benefit relat stock compens
expens drove ep beat quarter
price target nc
price target base ep estim risk thesi includ slower
procedur volum growth increas price pressur delay new product approv
expect deliv organ sale growth high-end med-tech led broad-bas growth
across segment geographi aid execut contribut recent acquisit
incorpor michigan stryker corpor one world largest medic technolog
compani offer orthoped implant well medic surgic equip orthoped implant
account revenu medsurg divis account nearli
neurotechnolog spine account remaind compani report sale billion
